|
|
"A comprehensive, collaborative elections resource."
|
Bid to Stockpile Bioterror Drugs Stymied by Setbacks
|
|---|
| Parent(s) |
Issue
|
| Contributor | RP |
| Last Edited | RP Sep 18, 2006 12:21pm |
| Logged |
0
|
| Category | Analysis |
| Media | Newspaper - New York Times |
| News Date | Monday, September 18, 2006 06:00:00 PM UTC0:0 |
| Description | The result was Project BioShield, a $5.6 billion effort to exploit the country’s top medical and scientific brains and fill an emergency medical cabinet with new drugs and vaccines for a host of threats. “We will rally the great promise of American science and innovation to confront the greatest danger of our time,” President Bush said in starting the program.
But the project, critics say, has largely failed to deliver.
What had begun as an effort to test and manufacture a safer, faster-acting vaccine has turned into an ugly battle between two biotech businesses.
Each has hired Washington lobbyists to attack its rival’s product and try to win over lawmakers and administration officials. Delivery of the new vaccine is far behind schedule, and a dispute between the Department of Health and Human Services and VaxGen, the company chosen to make the vaccine, could even end the deal. The only doses that have been added to the stockpile are of a decades-old vaccine that has generated complaints of serious side effects. |
| Share |
|
|
2¢
|
|
| Article | Read Full Article |
|
| Date |
Category |
Headline |
Article |
Contributor |
|
|
